EP News: Allied Professionals

Using data from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial, Lopes et  al (J Am Coll Cardiol 2018;71:1063, PMID 29519345) sought to determine the effect of digoxin on mortality in patients with atrial fibrillation (AF). ARISTOTLE is a pivotal trial involving ∼18,000 patients with AF and at least 1 risk factor for stroke with randomization to apixaban or warfarin. T he present study is a post hoc analysis of those patients who were on digoxin at baseline as compared with those not on digoxin as well as an analysis of patients taking digoxin during the course of the study compared to a propensity-matched group.
Source: Heart Rhythm - Category: Cardiology Authors: Source Type: research